Literature DB >> 10590054

Distinct requirements for optimal growth and In vitro expansion of human CD34(+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells.

V Ramsfjell1, D Bryder, H Björgvinsdóttir, S Kornfält, L Nilsson, O J Borge, S E Jacobsen.   

Abstract

Recently, primitive human bone marrow (BM) progenitors supporting hematopoiesis in extended (>60 days) long-term BM cultures were identified. Such extended long-term culture-initiating cells (ELTC-IC) are of the CD34(+)CD38(-) phenotype, are quiescent, and are difficult to recruit into proliferation, implicating ELTC-IC as the most primitive human progenitor cells detectable in vitro. However, it remains to be established whether ELTC-IC can proliferate and potentially expand in response to early acting cytokines. Here, CD34(+)CD38(-) BM ELTC-IC (12-week) were efficiently recruited into proliferation and expanded in vitro in response to early acting cytokines, but conditions for expansion of ELTC-IC activity were distinct from those of traditional (5-week) LTC-IC and murine long-term repopulating cells. Whereas c-kit ligand (KL), interleukin-3 (IL-3), and IL-6 promoted proliferation and maintenance or expansion of murine long-term reconstituting activity and human LTC-IC, they dramatically depleted ELTC-IC activity. In contrast, KL, flt3 ligand (FL), and megakaryocyte growth and development factor (MGDF) (and KL + FL + IL-3) expanded murine long-term reconstituting activity as well as human LTC-IC and ELTC-IC. Expansion of LTC-IC was most optimal after 7 days of culture, whereas optimal expansion of ELTC-IC activity required 12 days, most likely reflecting the delayed recruitment of quiescent CD34(+)CD38(-) progenitors. The need for high concentrations of KL, FL, and MGDF (250 ng/mL each) and serum-free conditions was more critical for expansion of ELTC-IC than of LTC-IC. The distinct requirements for expansion of ELTC-IC activity when compared with traditional LTC-IC suggest that the ELTC-IC could prove more reliable as a predictor for true human stem cell activity after in vitro stem cell manipulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590054

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells.

Authors:  Kohshi Ohishi; Barbara Varnum-Finney; Irwin D Bernstein
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.

Authors:  Ivar Østby; Leiv S Rusten; Gunnar Kvalheim; Per Grøttum
Journal:  J Math Biol       Date:  2003-04-23       Impact factor: 2.259

3.  Towards predictive models of stem cell fate.

Authors:  Sowmya Viswanathan; Peter W Zandstra
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 4.  Clinical gene therapy in hematology: past and future.

Authors:  J Richter; S Karlsson
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

5.  Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells.

Authors:  Colleen Delaney; Barbara Varnum-Finney; Keisuke Aoyama; Carolyn Brashem-Stein; Irwin D Bernstein
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

6.  Hematopoietic colony-forming cells derived from human embryonic stem cells.

Authors:  D S Kaufman; E T Hanson; R L Lewis; R Auerbach; J A Thomson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

7.  Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells.

Authors:  J Audet; C L Miller; S Rose-John; J M Piret; C J Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

9.  Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation.

Authors:  D Bryder; V Ramsfjell; I Dybedal; K Theilgaard-Mönch; C M Högerkorp; J Adolfsson; O J Borge; S E Jacobsen
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.